{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:12:10Z","timestamp":1787019130687,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100014565","name":"Bausch Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited real-life evidence with brodalumab in patients with plaque psoriasis in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine real-world effectiveness of brodalumab in Canadian routine care with a focus on clinician and patient-reported outcomes, as well as measuring continuation rates and persistency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis was conducted on data collected through the brodalumab patient support program (PSP) in Canada for patients initiating brodalumab between June 2018 (PSP launch)- June 2020 with a minimum of 16 weeks follow-up from first dose. Effectiveness was assessed by improvements in PASI, BSA and DLQI; continuation rates and persistency on therapy were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 864 patients (male, 59%; median age, 52 years) were included in the analysis. In a subset of patients with both baseline and follow-up scores, statistically significant improvements were observed: PASI improved from 13.9 to 1.8, BSA improved from 16.6% to 2.5% and DLQI improved from 16.2 to 2.9. Brodalumab demonstrated high continuation rates (89.9%), with similar rates in biologic-na\u00efve and biologic-experienced patients (92.1% and 88.6%, respectively) and in patients who received secukinumab or ixekizumab as their most recent biologic therapy (89.0% and 86.2%, respectively). Persistence at 6, 12, and 18 months was 82.0%, 69.9%, and 63.4%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The effectiveness of brodalumab was demonstrated in this Canadian routine care study, with significant improvements in disease severity and patient-reported outcomes. High continuation rates were achieved; including in patients previously treated with IL-17A inhibitors. Future studies will provide further evidence of brodalumab\u2019s benefits for the management of plaque psoriasis in the real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/12034754231168851","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T06:54:43Z","timestamp":1682060083000},"page":"226-235","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-7453","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Gaudet","sequence":"first","affiliation":[{"name":"Bausch Health, Canada Inc., Laval, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Yap","sequence":"additional","affiliation":[{"name":"Innomar Strategies Inc., Oakville, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-9988","authenticated-orcid":false,"given":"Shazia","family":"Hassan","sequence":"additional","affiliation":[{"name":"Innomar Strategies Inc., Oakville, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Barbeau","sequence":"additional","affiliation":[{"name":"Bausch Health, Canada Inc., Laval, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"bibr1-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"bibr2-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00518-8"},{"key":"bibr3-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23743"},{"key":"bibr4-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"bibr5-12034754231168851","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2022.346"},{"key":"bibr6-12034754231168851","unstructured":"CADTH CDR Clinical Review Report: Halobetasol propionate and tazarotene (Duobrii): Ottawa (ON). https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/clinical\/sr0638-duobrii-clinical-review-report.pdf"},{"key":"bibr7-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418811347"},{"key":"bibr8-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"issue":"5","key":"bibr9-12034754231168851","first-page":"Cd011535","volume":"5","author":"Sbidian E.","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr10-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00647-0"},{"key":"bibr11-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00690-5"},{"key":"bibr12-12034754231168851","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.4957"},{"key":"bibr13-12034754231168851","unstructured":"CADTH Health Technology Review: Biologics in Plaque Psoriasis. Ottawa (ON): CADTH. https:\/\/www.cadth.ca\/sites\/default\/files\/ES\/ES0357%20Biologics%20in%20Plaque%20Psoriasis_%20Final.pdf"},{"key":"bibr14-12034754231168851","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.4645"},{"key":"bibr15-12034754231168851","unstructured":"SILIQ\u2122 Product Monograph. Accessed 7 July 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00044076.PDF"},{"key":"bibr16-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"bibr17-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"bibr18-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.095"},{"key":"bibr19-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18068"},{"key":"bibr20-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"bibr21-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-71"},{"key":"bibr22-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"bibr23-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"bibr24-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"bibr25-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16931"},{"key":"bibr26-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.01.002"},{"key":"bibr27-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2022.02.007"},{"key":"bibr28-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15532"},{"key":"bibr29-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01907-y"},{"key":"bibr30-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.007"},{"key":"bibr31-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1716932"},{"key":"bibr32-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15106"},{"key":"bibr33-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00411-w"},{"key":"bibr34-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.013"},{"issue":"4","key":"bibr35-12034754231168851","first-page":"354","volume":"21","author":"Lebwohl M.","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"bibr36-12034754231168851","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00598-4"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754231168851","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754231168851","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754231168851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:49:50Z","timestamp":1777391390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754231168851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/12034754231168851"],"URL":"https:\/\/doi.org\/10.1177\/12034754231168851","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]}}}